Plasmodial folate synthesis pathway

The Plasmodial folate synthesis pathway is an essential metabolic route in Plasmodium parasites, such as Plasmodium falciparum, responsible for producing reduced folate cofactors necessary for DNA synthesis and amino acid metabolism (Müller et al., 2013). Unlike their human hosts, who primarily rely on dietary folate uptake, Plasmodium parasites possess a de novo synthesis pathway that is essential for their survival and replication within red blood cells (Hyde, 2005). This pathway involves several key enzymes, most notably dihydropteroate synthase (DHPS) and dihydrofolate reductase-thymidylate synthase (DHFR-TS) (Gregson & Plowe, 2005). Antifolate drugs, such as sulfadoxine and pyrimethamine, target these specific enzymes to disrupt the production of tetrahydrofolate, effectively halting parasite proliferation (Nzila, 2006). However, the clinical utility of targeting this pathway is increasingly challenged by the widespread emergence of genetic mutations in the parasite's dhfr and dhps genes, which confer high levels of drug resistance (Gregson & Plowe, 2005). Despite these challenges, the pathway remains a cornerstone of malaria chemotherapy and a focus for developing next-generation inhibitors that can bypass existing resistance mechanisms.

Other names

Plasmodium folate biosynthesis pathwayDe novo folate synthesis pathwayAntifolate target pathway

Inhibition of dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR) enzymes within the folate biosynthesis pathway, leading to the depletion of tetrahydrofolate and subsequent inhibition of DNA synthesis (Nzila, 2006; Gregson & Plowe, 2005).